This site is intended for US audiences only. If you are a resident of the European
Union, please
click here for the EU version of our site.
Paroxysmal nocturnal hemoglobinuria (PNH) is a progressive and life-threatening disease that causes thrombosis, end organ damage, impaired quality of life, and increased mortality.1-3
Click here
Important facts about PNH:
- Chronic hemolysis is the underlying cause of progressive morbidities and
mortality in PNH4
- Thrombosis is the leading cause of death in PNH1-3
- Early diagnosis drives effective PNH management
About PNH
- Monitoring hemolysis with lactate dehydrogenase (LDH) provides a more accurate assessment of PNH
- Evaluate your patients with myelodysplastic syndromes (MDS) at diagnosis and your patients with aplastic anemia (AA) at diagnosis and annually
.
*For US physicians only. Allowed in all states except DC, MA, ME, MN, and VT.
References: 1. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253-1258.2. Socié G, Mary J-Y, de Gramont A, et al, for the French Society of Haematology. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348:573-577. 3. Nishimura J-I, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine. 2004;83:193-207. 4. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233-1243.